Brilinta Tablets Dosage
Medically reviewed by Drugs.com. Last updated on May 9, 2022.
Acute Coronary Syndrome or a History of Myocardial Infarction
Initiate treatment with a 180 mg loading dose of BRILINTA. Administer 90 mg of BRILINTA twice daily during the first year after an ACS event. After one year, administer 60 mg of BRILINTA twice daily.
Coronary Artery Disease but No Prior Stroke or Myocardial Infarction
Administer 60 mg of BRILINTA twice daily. For all patients with ACS [see Dosage and Administration (2.1)].
Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
Initiate treatment with a 180 mg loading dose of BRILINTA and then continue with 90 mg twice daily for up to 30 days. The treatment effect accrued early in the course of therapy [see Clinical Studies (14.3)].
A patient who misses a dose of BRILINTA should take one tablet (their next dose) at its scheduled time.
For patients who are unable to swallow tablets whole, BRILINTA tablets can be crushed, mixed with water and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater) [see Clinical Pharmacology (12.3)].
Do not administer BRILINTA with another oral P2Y12 platelet inhibitor.
Frequently asked questions
- What medications disqualify you from donating blood/plasma?
- What foods should I eat or avoid when taking Brilinta?
- Can you drink alcohol while taking Brilinta?
- How long does it take for Brilinta to work?
- How long do I have to take Brilinta after a stent or heart attack?
- Brilinta vs Plavix: what's the difference?
- What pain medication can I take with Brilinta?
- Is Brilinta a blood thinner or antiplatelet?
- Is ticagrelor better than clopidogrel?
- Is there a generic for Brilinta?
- How long should Brilinta be held/stopped before surgery?
- Is ticagrelor a prodrug?
- What is Brilinta (ticagrelor) used for?
More about Brilinta (ticagrelor)
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Reviews (85)
- Patient tips
- Drug images
- Compare alternatives
- Pricing & coupons
- Generic availability
- En español
- Drug class: platelet aggregation inhibitors
- FDA approval history
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.